Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28514916 | 0.75 | PYGB (0.42) | PYGBCTSSCTSK | |
| SCHEMBL21058371 | 0.69 | PTPN1 (0.39) | — | |
| SCHEMBL31731230 | 0.69 | PTPN1 (0.39) | — | |
| SCHEMBL21137891 | 0.68 | CTSK (0.35) | PYGBCTSSCTSKPSENEN | |
| SCHEMBL21058397 | 0.68 | CTSK (0.35) | PYGBCTSSCTSKPSENEN | |
| SCHEMBL16869410 | 0.64 | CTSK (0.38) | CTSSCTSKPSENEN | |
| SCHEMBL19358982 | 0.61 | CTSS (0.44) | PYGBCTSSCTSKPSENEN | |
| SCHEMBL22605227 | 0.61 | CTSK (0.52) | CTSSCTSKPSENEN | |
| SCHEMBL25911505 | 0.61 | CTSK (0.52) | CTSSCTSKPSENEN | |
| SCHEMBL2721327 | 0.60 | CTSK (0.55) | CTSSCTSKPSENEN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2025-11-20 | — | — | US | disclosed |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | PYGB 601/4885CTSS 674/4885CTSK 331/4885 |
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, GLA | PYGB 760/4885CTSS 1085/4885CTSK 577/4885 |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, FUT6 | PYGB 802/4885CTSS 1129/4885CTSK 493/4885 |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | PYGB 760/4885CTSS 1085/4885CTSK 577/4885 |
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | SOST, FUT6, SLC5A1 | PYGB 675/4885CTSS 1006/4885CTSK 874/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | PYGB 601/4885CTSS 674/4885CTSK 331/4885 |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | PYGB 601/4885CTSS 674/4885CTSK 331/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | PYGB 601/4885CTSS 674/4885CTSK 331/4885 |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, FUT6 | PYGB 802/4885CTSS 1129/4885CTSK 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.